Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Parallel-arm, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of BFB759 in Patients With Atopic Dermatitis (COMPASS 2-AD)

NCT07105488 is registered in ClinicalTrials.gov with Bluefin Biomedicine, Inc. as lead sponsor.

NCT NCT07105488
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07105488 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Parallel-arm, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of BFB759 in Patients With Atopic Dermatitis (COMPASS 2-AD)
Lead sponsor
Bluefin Biomedicine, Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
July 15, 2025
Completion date
March 31, 2027
Enrollment
225 (estimated)
Sites
88

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis (ad)